Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.
Financial Results:
Alembic Pharmaceuticals Ltd reported Revenues for Q2FY25 of ₹1,648.00 Crores up from ₹1,595.00 Crore year on year, a rise of 3.32%.
Total Expenses for Q2FY25 of ₹1,499.00 Crores up from ₹1,471.00 Crores year on year, a rise of 1.9%.
Consolidated Net Profit of ₹153.00 Crores up 11.68% from ₹137.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.80, up 12.23% from ₹6.95 in the same quarter of the previous year.